Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mosenergo in the first half increased electricity generation by 0.5%

7/20/23 MSNG

VSMPO-AVISMA reported for 6 months of 2023 by RAS

7/20/23 VSMO

State Duma passed a law on the exclusion of foreign entities from the chain of ownership

7/20/23 MOEX

MMK closed the acquisition of the Tikhov mine

7/20/23 MAGN

Abbott reported for 6 months of 2023

7/20/23 ABT

The Newmont Goldcorp announced a quarterly dividend

7/20/23 NEM

Newmont reported for 6 months of 2023

7/20/23 NEM

PMI reported for 6 months of 2023

7/20/23 PM

American Airlines reported for 6 months of 2023

7/20/23 AAL

The Johnson & Johnson announced a quarterly dividend

7/20/23 JNJ